Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04489381
Recruitment Status : Recruiting
First Posted : July 28, 2020
Last Update Posted : December 31, 2020
Sponsor:
Information provided by (Responsible Party):
Romark Laboratories L.C.

Brief Summary:
Trial to evaluate the efficacy and safety of nitazoxanide in the treatment of colds due to enterovirus/rhinovirus infection

Condition or disease Intervention/treatment Phase
Enterovirus Rhinovirus Drug: Nitazoxanide Drug: Placebo Dietary Supplement: Vitamin Super B-Complex Phase 3

Detailed Description:
Multicenter, randomized, double-blind trial to evaluate the efficacy and safety of nitazoxanide in the treatment of colds due to enterovirus/rhinovirus infection

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Phase 3, A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Actual Study Start Date : August 13, 2020
Estimated Primary Completion Date : May 31, 2021
Estimated Study Completion Date : May 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Nitazoxanide
Two nitazoxanide 300 mg tablets orally twice daily for 5 days
Drug: Nitazoxanide
Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
Other Names:
  • NTZ (nitazoxanide)
  • NT-300

Dietary Supplement: Vitamin Super B-Complex
Vitamin Super B-Complex administered orally twice daily to maintain the blind

Placebo Comparator: Placebo
Two placebo tablets orally twice daily for 5 days
Drug: Placebo
Two placebo tablets administered orally twice daily with food for 5 days

Dietary Supplement: Vitamin Super B-Complex
Vitamin Super B-Complex administered orally twice daily to maintain the blind




Primary Outcome Measures :
  1. Time from First Dose to Sustained Response [ Time Frame: 21 days ]
    Time from First Dose to Sustained Response in Subjects with Laboratory-Confirmed Enterovirus/Rhinovirus Infection based upon the FLU-PRO Instrument


Secondary Outcome Measures :
  1. Proportion of Subjects Requiring Systemic Antibiotics [ Time Frame: 21 days ]
    Proportion of Subjects Requiring Systemic Antibiotics for an Infection Secondary to Enterovirus/Rhinovirus, including pneumonia, otitis media, bronchitis, sinusitis or pharyngitis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 120 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female outpatients at least 12 years of age
  • Presence of clinical signs and/or symptoms consistent with worsening or stable cold due to Enterovirus/Rhinovirus infection (one of the following is required):

    1. Presence of at least two respiratory symptom domains (head, throat, nose, chest, cough) with a score of ≥2 as determined by Screening FLU-PRO OR
    2. Presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by Screening FLU-PRO with pulse rate ≥90 OR
    3. Presence of at least one respiratory symptom domain (head, throat, nose, chest, cough) with a score of ≥2 as determined by Screening FLU-PRO with respiratory rate ≥16

AND patient reported assessment that symptoms are present, the symptoms are not consistent with the subject's usual health, the symptoms interfere with daily activities, and the symptoms have worsened or remained the same relative to the previous day, as confirmed by responses to questions in the Screening FLU-PRO.

  • Onset of symptoms no more than 72 hours before enrollment in the trial. Onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (head, throat, nose, chest, or cough symptoms).
  • Willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the subject diary and all protocol procedures.

Exclusion Criteria:

  • Subjects who experienced a previous episode of acute upper respiratory tract infection, otitis, bronchitis or sinusitis or received antibiotics for these conditions within two weeks prior to and including study day 1.
  • Severely immunodeficient persons including:

    1. Subjects with immunologic disorders or receiving immunosuppressive therapy (e.g., for organ or bone marrow transplants, immunomodulatory therapies for certain autoimmune diseases).
    2. Subjects with untreated human immunodeficiency viruses (HIV) infection or treated human immunodeficiency viruses (HIV) infection with a CD4 count below 350 cells/mm3 in the last six months.
    3. Subjects actively undergoing systemic chemotherapy or radiotherapy treatment for malignancy.
    4. Subjects using steroids as maintenance therapy for a chronic condition.
  • Subjects with active respiratory allergies or subjects expected to require anti- allergy medications during the study period for respiratory allergies.
  • Females of childbearing potential who are either pregnant or sexually active without the use of birth control. Female subjects of child-bearing potential that are sexually active must have a negative baseline pregnancy test and must agree to continue an acceptable method of birth control for the duration of the study and for 1 month post-treatment. A double barrier method, oral birth control pills administered for at least 2 monthly cycles prior to study drug administration, an Intrauterine Device (IUD), or medroxyprogesterone acetate administered intramuscularly for a minimum of one month prior to study drug administration are acceptable methods of birth control for inclusion into the study. Female subjects are considered of childbearing potential unless they are postmenopausal (absence of menstrual bleeding for 1 year - or 6 months if laboratory confirmation of hormonal status), or have had a hysterectomy, bilateral tubular ligation or bilateral oophorectomy.
  • Subjects residing in the same household with another subject participating in the study.
  • Treatment with any investigational drug or vaccine therapy within 30 days prior to screening and willing to avoid them during the course of the study.
  • Receipt of any dose of nitazoxanide (NTZ) within seven days prior to screening.
  • Known sensitivity to nitazoxanide (NTZ) or any of the excipients comprising the study medication.
  • Subjects unable to swallow oral tablets or capsules.
  • Subjects with known severe heart, lung, neurological or other systemic disease that the Investigator believes could preclude safe participation.
  • Subjects likely or expected to require hospitalization unrelated to cold during the study period.
  • Subjects who, in the judgment of the Investigator, will be unlikely to comply with the requirements of this protocol including completion of the subject diary.
  • Subjects taking medications considered to be major CYP2C8 substrates.
  • Persons with any clinical sign or symptoms suggestive of severe systemic illness with COVID-19, including the following:

    1. shortness of breath at rest,
    2. resting pulse ≥125 beats per minute,
    3. resting respiratory rate ≥ breaths per minute, or
    4. SpO2 ≤ 93% on room air at sea level.
  • Subjects known to have a diagnostic test positive for SARS-CoV-2 or influenza infection within the preceding three weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04489381


Contacts
Layout table for location contacts
Contact: Matthew Bardin 813-282-8544 matthew.bardin@romark.com

Locations
Layout table for location information
United States, Arkansas
HealthStar Research LLC Recruiting
Hot Springs, Arkansas, United States, 71913
Contact: Romark    877-925-4642      
United States, Florida
Invesclinic US LLC Recruiting
Fort Lauderdale, Florida, United States, 33308
Contact: Romark    877-925-4642      
United States, New York
RH Medical Urgent Care Recruiting
Bronx, New York, United States, 10456
Contact: Romark    877-925-4642      
Sponsors and Collaborators
Romark Laboratories L.C.
Layout table for additonal information
Responsible Party: Romark Laboratories L.C.
ClinicalTrials.gov Identifier: NCT04489381    
Other Study ID Numbers: RM08-3009
First Posted: July 28, 2020    Key Record Dates
Last Update Posted: December 31, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Romark Laboratories L.C.:
Enterovirus
Rhinovirus
Additional relevant MeSH terms:
Layout table for MeSH terms
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Nitazoxanide
Antiparasitic Agents
Anti-Infective Agents